Tonix Pharma (TNXP) has issued an update.
The Company has made significant strides with its Tonmya™ product for fibromyalgia management, having recently concluded a final pre-NDA meeting with the FDA and confirming that the data package is sufficient for NDA submission. They remain on track to submit the NDA in the latter half of 2024. While these developments are promising, investors should note that forward-looking statements involve risks and uncertainties, and actual outcomes may differ from expectations.
For detailed information about TNXP stock, go to TipRanks’ Stock Analysis page.
